Comprehensive imaging and quantification of blood flow for investigating ocular diseases without additional contrast agent

项目摘要/摘要 物理科学公司(PSI)与纽约大学(NYU)医学院合作 建议开发一种新的眼科成像平台来表征视网膜的形态和 监测眼部血流异常。该平台将结合非侵入性测量 基于光学相干断层扫描的视网膜/脉络膜结构和眼血流 使用线扫描多普勒流量计(LSDF)的现场半定量全球流动显示。这个 在同一成像平台中组合这两种成像模式可实现全面的 评估视网膜和脉络膜的血流。这一新的成像平台将使成像 在视力正常或患有各种视网膜疾病的动物和人类受试者身上的研究。之前的PSI 开发先进眼科成像系统的经验与我们的合作者的专业知识相结合 在眼科领域，我们将发挥杠杆作用，确保这一重要的研发项目取得成功。 在第一阶段计划期间，将对正常和患病的啮齿动物进行成像，进行可行性研究 使用台式仪器的模型。临床原型仪器将被制造和测试。 临床上在纽约大学二期人群中突出表现为血液动力学视网膜生物标志物。我们 选择关注导致失明的主要原因的疾病，包括老年性黄斑 退行性变(AMD)、糖尿病视网膜病变(DR)和青光眼，以证明我们的新技术的临床实用性 系统。我们将招募健康的人作为参考，AMD、DR和青光眼的受试者在 疾病的严重性范围很广。在所有这些条件下，记录体内血流的能力将 提供新的信息，将开辟新的诊断和治疗途径。

Project Summary/Abstract Physical Sciences Inc. (PSI) in collaboration with New York University (NYU) School of Medicine proposes to develop a novel ophthalmic imaging platform for characterizing retinal morphology and monitoring ocular blood flow abnormalities. This platform will combine non-invasive measurements of retina/choroid structure and ocular blood flow based on optical coherence tomography (OCT) and wide- field semi-quantitative global flow visualization using line-scanning Doppler flowmetry (LSDF). The combination of these two imaging modalities within the same imaging platform enables comprehensive assessment of blood flow in the retina and choroid. This novel imaging platform will enable imaging studies in animals and human subjects with normal vision or with various retinal diseases. Prior PSI experience in developing advanced ophthalmic imaging systems coupled with our collaborators' expertise in Ophthalmology will be leveraged to ensure the successful outcome of this important R&D program. A feasibility study will be performed during the Phase I program by imaging normal and diseased rodent models using a benchtop instrument. A clinical prototype instrument will be manufactured and tested clinically in Phase II in the NYU population of patients to highlight hemodynamic retinal biomarkers. We choose to focus on diseases that are the leading causes of blindness including, age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma to demonstrate the clinical utility of our novel system. We will recruit healthy individuals to set a reference, and subjects with AMD, DR, and glaucoma at a wide range of disease severity. In all of these conditions, the ability to record in vivo blood flow will provide novel information that will open new diagnostic and treatment avenues.